MAXIPHARMA
ActiveSummary
MAXIPHARMA has been active since 1997 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €227,467 and a net result of €89,731, of which €169,644 non-recurring income. Equity has been shrinking by about 7% per year since 2018. Its solvency ranks better than 91% of 22,726 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 21-04-1997 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Establishment unit
- 2.082.184.281 6060 Charleroi, since 13-06-1997
- Financial year end
- 31 December
- Peppol
- Reachable since 05-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
Annual accounts 2025
- Gross margin
- €129,621
- ▲ 107×
- Turnover
- ≈ €410,000
- estimated
- Profit
- €89,731
- Equity
- €227,467
- ▲ 65.1%
- Total assets
- €269,211
- ▲ 80.7%
- 2025 accounts filed 30 days after the deadline
Filed on 30-08-2026
Score breakdownraises risk1 change of registered office in 24 monthslowers riskLiquidity: current ratio 6.45, cash €267,253Equity €227,467 (84.5% of total assets)Founded in 1997Show the evidence
Checked score
Score 2025
99
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 93% of micro companies in retail trade (NACE 47)
Financial strength · tick: 2024
Strong
Solvency
100=
equity 84.5% of total assets
Liquidity
97-3
short-term debt 15.5% · cash 99.3%
Profitability
100+90
return on assets 33.3%
Bankruptcy probability within 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025lowest value
03-2025: 0.1%● unchanged vs 02-2025lowest value
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.6%▲ +0.5 percentage points vs 08-2025highest value
10-2025: 0.2%▼ -0.4 percentage points vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.4%▲ +0.2 percentage points vs 07-2026
09-2026: 0.1%▼ -0.3 percentage points vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Credit of up to €22,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 6.45 (9.86 in 2024), above the usual 1.5. Short-term debt is 15.5% and cash 99.3% of total assets. 15.5% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 92% of them on solvency, 95% on liquidity, 96% on profitability and 89% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €227,467
raises risk · 2025 accounts filed 30 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-08-2026, 30 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
30 days late
2024
28 days late
2023
29 days late
2022
29 days late
2021
25 days late
2020
25 days late
2019
42 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 30 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials
Financials · financial year 2025, micro format
2025 annual accounts filed 30 days after the deadline Filed on 30 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00454480.
Annual accounts 2025 filed on 30-08-2026 at the NBB all 29 filings
Turnover
≈ €410,000
Estimated: probably between €280,000 and €800,000
Total assets
€269,211▲ 80.7%
2024 · €149,012
Net result
€89,731
2024 · -€9,992
Working capital
€227,467▲ 128%
2024 · €99,880
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result for 2025 is a profit of €127,290, after a loss of €9,079 in 2024. It is the highest result since 2021.
Operating result€127,290
2025
Net result€89,731
2025
Total assets€269,211
2025
Equity€227,467
2025
Debt€41,744
2025
Working capital€227,467
2025
Return on assets (ROA)33.3%
2025
Solvency84.5%
2025
Current ratio6.45
2025
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Retail trade (NACE 47). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€8,597--€96-€4,853▼ 4,934%€3,703€1,611▼ 56.5%-€6,948-€9,079▼ 30.7%€127,290
Net result€7,846--€1,204-€5,995below the sector's middle half▼ 398%€2,592within the sector's middle half€429within the sector's middle half▼ 83.4%-€8,390below the sector's middle half-€9,992below the sector's middle half▼ 19.1%€89,731above the sector's middle half
Equity€236,446-€226,241▼ 4.3%€210,246above the sector's middle half▼ 7.1%€197,839above the sector's middle half▼ 5.9%€183,268above the sector's middle half▼ 7.4%€154,878above the sector's middle half▼ 15.5%€137,736above the sector's middle half▼ 11.1%€227,467above the sector's middle half▲ 65.1%
Total assets€256,358-€266,785▲ 4.1%€259,982within the sector's middle half▼ 2.6%€232,519within the sector's middle half▼ 10.6%€217,516within the sector's middle half▼ 6.5%€191,492within the sector's middle half▼ 12.0%€149,012within the sector's middle half▼ 22.2%€269,211within the sector's middle half▲ 80.7%
Debt€19,913-€40,544▲ 104%€49,736▲ 22.7%€34,680▼ 30.3%€34,249▼ 1.2%€36,614▲ 6.9%€11,275▼ 69.2%€41,744▲ 270%
Working capital€169,698-€155,615▼ 8.3%€148,561above the sector's middle half▼ 4.5%€140,487above the sector's middle half▼ 5.4%€131,668above the sector's middle half▼ 6.3%€110,260above the sector's middle half▼ 16.3%€99,880above the sector's middle half▼ 9.4%€227,467above the sector's middle half▲ 128%
Solvency92.2%-84.8%▼ 7.4pp80.9%above the sector's middle half▼ 3.9pp85.1%above the sector's middle half▲ 4.2pp84.3%above the sector's middle half▼ 0.8pp80.9%above the sector's middle half▼ 3.4pp92.4%above the sector's middle half▲ 11.6pp84.5%above the sector's middle half▼ 7.9pp
Current ratio9.52-5.87▼ 3.654.41above the sector's middle half▼ 1.465.53above the sector's middle half▲ 1.124.99above the sector's middle half▼ 0.554.01above the sector's middle half▼ 0.989.86above the sector's middle half▲ 5.856.45above the sector's middle half▼ 3.41
Return on assets (ROA)3.1%--0.5%▼ 3.5pp-2.3%below the sector's middle half▼ 1.9pp1.1%within the sector's middle half▲ 3.4pp0.2%within the sector's middle half▼ 0.9pp-4.4%below the sector's middle half▼ 4.6pp-6.7%below the sector's middle half▼ 2.3pp33.3%above the sector's middle half▲ 40.0pp
above
within
below
The sector band is the middle half of the companies in Retail trade (NACE 47). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €269,211
Equity
€227,467 ▲ 65.1%
Debt
€41,744 ▲ 270%
Debt's share of the balance-sheet total rises from 7.6% to 15.5%. Equity and debt are higher.
Key figures and ratios
Debt to equity
0.18▲
2024 · 0.08
ROE
39.4%▲
2024 · -7.3%
Debt ≤ 1 year
€41,744▲
2024 · €11,275
Income taxes
€36,646▲
2024 · €128
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €2,000 | - | - | - | - |
| Depreciation and write-downs of the year | €8,794 | €8,213 | €8,213 | €6,762 | - |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Comparable companies
These companies have the same main activity as MAXIPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €249,000 and €322,000, founded between 1995 and 2000.
| Company | Founded | Total assets | Equity | Gross margin | Net result | FTE | Financial year |
|---|---|---|---|---|---|---|---|
| MAXIPHARMA Charleroi | 1997 | €269,211 | €227,467 | €129,621 | €89,731 | - | 2025 |
| APOTHEEK BEERT - VERSWIJVEL Laakdal | 1996 | €290,401 | €123,676 | €126,016 | €41,332 | 0.8 | 2026 |
| Apotheek Anselmo Antwerpen | 1998 | €249,318 | €150,239 | €115,790 | €25,688 | 1 | 2025 |
| PHARMACIE FAILLY La Louvière | 2000 | €300,445 | €178,502 | €139,968 | €4,645 | - | 2025 |
| PHARMACIE BAUDOUX M.C. Gerpinnes | 1995 | €321,711 | €205,617 | €105,207 | €5,187 | - | 2025 |
| Magistra - Pharma Schaarbeek | 1998 | €304,456 | €187,834 | €118,127 | €35,189 | - | 2025 |
| LEEMAN APOTHEEK Sint-Jans-Molenbeek | 1996 | €310,011 | €18,993 | €119,819 | €78,326 | - | 2025 |
They were chosen from the 3,936 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Companies with the same profile, two years later
Historical observationIn July 2024, 31,368 companies had the same profile as MAXIPHARMA has now. Two years later, 0.5% had gone bankrupt and 93.5% were still going.
- Micro
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.5%
went bankrupt
5.9%
stopped otherwise
93.5%
was still going
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of MAXIPHARMA itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,445 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,368 companies, not a prediction for MAXIPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | - | - | - | €169,644 | - |
| Remuneration, social security and pensions62 | - | - | - | - | - | - | €764 | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €8,542 | €9,927 | €11,402 | €8,794 | €8,213 | €8,213 | €6,762 | - | - |
| Other operating charges640/8 | - | - | - | €2,628 | €2,702 | €2,778 | €2,765 | €2,331 | ▼ 15.7% |
| Gross operating margin9900 | €19,274 | €12,205 | €9,303 | €15,125 | €12,526 | €4,042 | €1,212 | €129,621 | ▲ 107× |
| Operating profit (loss)9901 | €8,597 | -€96 | -€4,853 | €3,703 | €1,611 | -€6,948 | -€9,079 | €127,290 | - |
| Financial income75/76B | - | - | - | €243 | €1 | €189 | €570 | €443 | ▼ 22.3% |
| Recurring financial income75 | €527 | €405 | €397 | €243 | €1 | €189 | €570 | €443 | ▼ 22.3% |
| Financial charges65/66B | - | - | - | €1,243 | €1,071 | €1,292 | €1,355 | €1,356 | ▲ 0.1% |
| Recurring financial charges65 | €1,228 | €1,449 | €1,430 | €1,182 | €1,071 | €1,259 | €1,355 | €1,356 | ▲ 0.1% |
| Non-recurring financial charges66B | - | - | - | €62 | - | €33 | - | - | - |
| Profit (loss) for the period before taxes9903 | €7,846 | -€1,141 | -€5,886 | €2,702 | €541 | -€8,051 | -€9,864 | €126,377 | - |
| Income taxes67/77 | - | €64 | €109 | €110 | €112 | €339 | €128 | €36,646 | ▲ 286× |
| Profit (loss) for the period9904 | €7,846 | -€1,204 | -€5,995 | €2,592 | €429 | -€8,390 | -€9,992 | €89,731 | - |
| Profit (loss) for the period to be appropriated9905 | €7,846 | -€1,204 | -€5,995 | €2,592 | €429 | -€8,390 | -€9,992 | €89,731 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €256,358 | €266,785 | €259,982 | €232,519 | €217,516 | €191,492 | €149,012 | €269,211 | ▲ 80.7% |
| Fixed assets21/28 | €66,747 | €79,239 | €67,837 | €61,043 | €52,831 | €44,618 | €37,856 | - | - |
| Tangible fixed assets22/27 | €66,747 | €79,239 | €67,837 | €61,043 | €52,831 | €44,618 | €37,856 | - | - |
| Land and buildings22 | - | - | - | €54,955 | €49,193 | €43,430 | €37,856 | - | - |
| Furniture and vehicles24 | - | - | - | €6,088 | €3,638 | €1,188 | - | - | - |
| Current assets29/58 | €189,611 | €187,546 | €192,145 | €171,476 | €164,686 | €146,874 | €111,155 | €269,211 | ▲ 142% |
| Stocks and contracts in progress3 | €39,085 | €41,141 | €41,251 | €38,333 | €34,535 | €27,409 | €5,485 | - | - |
| Stocks30/36 | - | - | - | €38,333 | €34,535 | €27,409 | €5,485 | - | - |
| Amounts receivable within one year40/41 | €30,735 | €25,433 | €17,864 | €20,321 | €23,457 | €19,973 | €17,072 | €1,086 | ▼ 93.6% |
| Trade receivables40 | - | - | - | €11,237 | €16,655 | €17,080 | €11,250 | €162 | ▼ 98.6% |
| Other amounts receivable41 | - | - | - | €9,085 | €6,802 | €2,892 | €5,821 | €924 | ▼ 84.1% |
| Cash at bank and in hand54/58 | €118,796 | €119,016 | €129,719 | €111,026 | €104,847 | €95,623 | €86,587 | €267,253 | ▲ 209% |
| Deferred charges and accrued income490/1 | - | - | - | €1,796 | €1,847 | €3,869 | €2,012 | €871 | ▼ 56.7% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €256,358 | €266,785 | €259,982 | €232,519 | €217,516 | €191,492 | €149,012 | €269,211 | ▲ 80.7% |
| Equity10/15 | €236,446 | €226,241 | €210,246 | €197,839 | €183,268 | €154,878 | €137,736 | €227,467 | ▲ 65.1% |
| Contributions10/11 | €6,197 | €6,197 | - | €6,197 | €6,197 | €6,197 | €6,197 | €6,197 | = |
| Reserves13 | €230,248 | €220,044 | €204,049 | €191,641 | €177,070 | €148,681 | €131,539 | €221,270 | ▲ 68.2% |
| Non-distributable reserves130/1 | - | - | - | €1,859 | €1,859 | €1,859 | €1,859 | €1,859 | = |
| Reserves not available under the articles1311 | - | - | - | €1,859 | €1,859 | €1,859 | €1,859 | €1,859 | = |
| Distributable reserves133 | - | - | - | €189,782 | €175,211 | €146,821 | €129,680 | €219,411 | ▲ 69.2% |
| Amounts payable17/49 | €19,913 | €40,544 | €49,736 | €34,680 | €34,249 | €36,614 | €11,275 | €41,744 | ▲ 270% |
| Amounts payable after more than one year17 | - | €8,613 | €6,152 | €3,691 | €1,231 | - | - | - | - |
| Financial debts170/4 | - | - | - | €3,691 | €1,231 | - | - | - | - |
| Amounts payable within one year42/48 | €19,913 | €31,931 | €43,584 | €30,989 | €33,018 | €36,614 | €11,275 | €41,744 | ▲ 270% |
| Current portion of amounts payable after more than one year42 | - | - | - | €2,461 | €2,461 | €1,231 | - | - | - |
| Trade debts44 | €7,044 | €13,939 | €23,965 | €6,826 | €7,004 | €8,480 | €4,060 | €1,665 | ▼ 59.0% |
| Suppliers440/4 | - | - | - | €2,661 | €3,249 | €4,680 | - | €1,665 | - |
| Bills of exchange payable441 | - | - | - | €4,165 | €3,755 | €3,800 | €4,060 | - | - |
| Taxes, remuneration and social security45 | - | - | - | €9,810 | €9,221 | €10,572 | €2,211 | €37,415 | ▲ 17× |
| Taxes450/3 | - | - | - | €7,614 | €7,065 | €8,331 | €2,211 | €37,415 | ▲ 17× |
| Remuneration and social security454/9 | - | - | - | €2,196 | €2,156 | €2,241 | - | - | - |
| Other amounts payable47/48 | - | - | - | €11,892 | €14,332 | €16,332 | €5,005 | €2,664 | ▼ 46.8% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €7,846 | -€1,204 | -€5,995 | €2,592 | €429 | -€8,390 | -€9,992 | €89,731 | - |
| + Depreciation and write-downs630 | €8,542 | €9,927 | €11,402 | €8,794 | €8,213 | €8,213 | €6,762 | - | - |
| Operating cash flow (approximation) | €16,389 | €8,722 | €5,407 | €11,386 | €8,642 | -€177 | -€3,230 | €89,731 | - |
| Investment in fixed assets (approximation) | - | -€22,419 | €0 | -€2,000 | €0 | €0 | €0 | - | - |
| Change in cash | - | €220 | €10,703 | -€18,694 | -€6,179 | -€9,224 | -€9,037 | €180,667 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 29 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 30-08-2026 | 2026-00454480 | NBB |
| 31-12-2024 | micro format | 28-08-2025 | 2025-00462277 | |
| 31-12-2023 | micro format | 29-08-2024 | 2024-00404611 | |
| 31-12-2022 | micro format | 29-08-2023 | 2023-00421295 | |
| 31-12-2021 | micro format | 25-08-2022 | 2022-20379486 | |
| 31-12-2020 | micro format | 25-08-2021 | 2021-52500336 | |
| 31-12-2019 | micro format | 11-09-2020 | 2020-52700384 | |
| 31-12-2018 | micro format | 19-08-2019 | 2019-46900532 | |
| 31-12-2017 | micro format | 19-07-2018 | 2018-34400288 | |
| 31-12-2016 | micro format | 31-08-2017 | 2017-52400309 |
Board & ownership
Directors
Directors
1 director, no change since 2022
Myriam BRÖSE
Current
Director (not named in the articles) · appointed in the act of 09-12-2022 · earlier manager, until 09-12-2022 · term without a fixed end · listed in the 2025 annual accounts, filed on 30-08-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 09-12-2022Owners and capital
Capital transactions
Capital over time
- 09-12-2022 Converted to unavailable equity · €8,056.33
Mandate history
1 person, 1 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Myriam BRÖSE |
|
Articles of association
Board and representation
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Si personne morale administrateur unique,représentant permanent suppléant peut être désigné conformément dernier alinéa article 2:55 CSA…”“Rémunération administrateur, assemblée générale à la majorité absolue des voix ou actionnaire unique détermine ou confirme montant fixe ou…”
Capital, shares and profit
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Héritiers et légataires ne devenant pas de plein droit actionnaires tenus de solliciter agrément selon mêmes formalités, réponse affirmative…”
Audit, dissolution and liquidation
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Si plusieurs liquidateurs forment collège, plus étendus conférés par 2:87. et suivants CSA”
Articles of association, deed of 09-12-2022 (in French)
Network & group
MAXIPHARMA shares no director with another company.
Companies at the same address
2 other companiesConnections & network
1 current directorThe network starts from the directors of MAXIPHARMA. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
30-08
micro format · 30 days late
2025
31-12
Financial
Back to profitnet €89,731
The net result is €89,731, after 2 loss-making years.
31-12
Financial
Equity above €200,000equity €227,467 ▲65.1%
Equity rises from €137,736 to €227,467.
28-08
micro format · 28 days late
18-08
Gazette deed
Registered office moved within Charleroi2 points ▸
Gazette deed
Registered office moved within Charleroi
2 points ▸
- Board meeting, 02-08-2025
- Registered-office move, 6000 Charleroi, rue de la Neuvilte, 66/111
2024
31-12
Financial
Weakest financial yearnet -€9,992
The net result drops to -€9,992, the lowest from 2018 to 2025. It recovers the following year.
31-12
Financial
Liquidity more than doubledcurrent ratio 9.86
The current ratio rises from 4.01 to 9.86. Short-term debt falls from €36,614 to €11,275.
29-08
micro format · 29 days late
2023
29-08
micro format · 29 days late
2022
09-12
Gazette deed
Change of role: Myriam BRÖSE, from manager to directorLegal-form conversion · Capital conversion · Reserve release10 points ▸
Gazette deed
Change of role: Myriam BRÖSE, from manager to director
Legal-form conversion · Capital conversion · Reserve release10 points ▸
- Legal-form conversion, “société à responsabilité limitée” (deed in French)
- Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
- Reserve release, “suppression”, 8056.33 (deed in French)
- Other provision, “obligation de libération du capital non appelé de l'ancienne SPRL, exemption de libération des apports” (deed in French)
- Amendment of the articles
- Capital
- Director resignation, Myriam BRÖSE (manager)
- Director appointment, Myriam BRÖSE (director (not named in the articles))
- Director discharge, Myriam BRÖSE
- Registered office clause, “Chaussée de Fleurus 25, Charleroi (6060-Gilly)” (deed in French)
25-08
micro format · 25 days late
2021
31-12
Financial
Back to profitnet €2,592
The net result is €2,592, after 2 loss-making years.
Show earlier events
25-08
micro format · 25 days late
2020
11-09
micro format · 42 days late
2019
19-08
micro format · 19 days late
2018
19-07
micro format · 12 days before the deadline
2017
31-08
micro format · 31 days late
1997
29-04
Gazette deed
Incorporation
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
MAXIPHARMA in French
Enterprise number
0460.509.874
Legal form
Private limited company
Status
Active, normale toestand
Founded
21-04-1997
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 09-12-2022 (in French)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Région Wallonne, établir ou supprimer sièges administratifs,d'exploitation,agences et succursales en Belgique ou à l'étranger par simple…”
deed of 09-12-2022 (in French)Registered office and establishments
Registered office
Rue de la Neuville 66, 6000 Charleroi, Belgium
Former registered office
6060 Charleroi until 02-08-2025 · act of 18-08-2025
Establishment unit
Chaussée de Fleurus 25, 6060 Charleroi since 13-06-1997 · unit number 2.082.184.281
Activities
NACEBEL 202547730
Retail sale of pharmaceutical products main activity
Codes under NACEBEL 2008
47730
Retail trade main activity
Codes under NACEBEL 2003
52310
main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 09-12-2022 (in French)
“L'organisation et l'exploitation d'officines de pharmacie et de tous services au profit de la pharmacologie et notamment l'étude,la…”
6 activities
- L'organisation et l'exploitation d'officines de pharmacie et de tous services au profit de la pharmacologie et notamment l'étude,la fabrication,l'importation et l'exportation,le négoce et la commercialisation de produits chimiques,pharmaceutiques,biologiques,homéopathiques et diététiques,de produits phytopharmaceutiques et vétérinaires,d'articles de droguerie et d'herboristerie,de parfumerie,d'hygiène et d'entretien,d'appareils,instruments et accessoires de chirurgie,médecine et médecine vétérinaires,d'acoustique et d'orthopédie et tous autres produits et objets s'y rapportant ou pouvant y être adjoints utilement.
- Elle pourra réaliser son objet en tous lieux,de toutes les manières qui lui paraîtront le mieux appropriées.
- Elle pourra notamment négocier tous contrats et accomplir toutes opérations généralement quelconques,industrielles,commerciales,mobilières et immobilières,civiles ou financières se rapportant directement ou indirectement,en ordre principal ou accessoire à son objet social ou susceptibles de le développer.
- Elle peut également s'intéresser par toutes voies dans toutes affaires,entreprises ou sociétés ayant un objet analogue,similaire ou connexe ou qui sont de nature à favoriser le développement de sa propre activité.
- Elle peut assurer la détention et la gestion pour compte propre d'un patrimoine de valeurs mobilières et immobilières.
- Elle peut garantir les engagements de tiers,notamment de ses gérants et associés.
Invoicing and payment
VAT number
BE 0460.509.874
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Fourth Tuesday of June at 11:00
deed of 09-12-2022 (in French)Recognitions · licences · registrations
Food safety, FASFC
1 siteCharleroiunit number 2.082.184.281
Sites & property
Location
Buildings and parcels at the addresses
Ground area
1,414 m²
Building footprint
217 m²
Building volume
7,000 m³
Tallest building: 42.0 m.
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 52302A1194/00C003 | Wallonia | 884 m² | 1 · 157 m² | 42.0 m · 13 |
| 52026C0285/00L002 | Wallonia | 529 m² | 1 · 59 m² | 14.6 m · 4 |